Findings

What do systematic reviews say?

1,230 questions · 1,303 findings · 326 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 73 · 5.6%GRADE not reported 21 · 1.6%Very low 497 · 38.1%Low 403 · 30.9%Moderate 245 · 18.8%High 64 · 4.9%

Non‐specialist‐led vs specialist‐led follow‐up after primary cancer treatment

Depressive symptoms · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal

Non‐specialist‐led showed no clear difference in depression (at 12 months) HADS‐Depression subscale (higher scores… compared with specialist‐led follow‐up after primary cancer treatment (high certainty).

1 finding from 1 review

Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors 2019 · Cochrane Headline outcomes only
MD 0.03
1266 participants
High

Biofeedback vs counseling

Composite Primary Symptom Reduction Score (CPSR) Scale from: ‐100 to 100 Higher score = better · people with irritable bowel syndrome

1 finding from 1 review

Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
Low

Multi‐component psychological intervention (with biofeedback) vs no intervention

Composite Primary Symptom Reduction Score (CPSR) Scale from: ‐100 to 100 Higher score = better · people with irritable bowel syndrome

1 finding from 1 review

Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 101 participants
Very low

Multi‐component psychological intervention (with biofeedback) vs attention control

Composite Primary Symptom Reduction Score (CPSR) Scale from: ‐100 to 100 Higher score = better · people with irritable bowel syndrome

1 finding from 1 review

Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 80 participants
Very low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Physical functioning component of health‐related quality of life, measured using various scales · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Quality of life Kansas City Cardiomyopathy Quality‐of‐Life questionnaire (higher scores indicate better quality of life) · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

QoL · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 163 participants
GRADE not reported

Yoga vs an active intervention

Incontinence‐specific quality of life · women with urge‐predominant urinary incontinence

1 finding from 1 review

Yoga for treating urinary incontinence in women 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Selexipag vs placebo

mPAP (the higher the mPAP, the worse the pulmonary hypertension) · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

PVR · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Prostacyclin vs control

mPAP (the higher the mPAP, the worse the pulmonary hypertension) · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1132 participants
Low

Prostacyclin vs control

PVR · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 658 participants
Moderate

Intervention not reported

Quality of life (QoL) Inflammatory Bowel Disease Questionnaire (IBDQ) (scale: 32 to 224; higher score = better QoL) · Patients with active Crohn's disease

1 finding from 1 review

Adalimumab for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 714 participants
Moderate

Palliative care vs usual care

Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Palliative care interventions for people with multiple sclerosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Very low

Pregabalin vs placebo

Self‐reported pain relief ‐ NPSI: ranges from 0 to 100. Higher scores are indicative of neuropathic pain. · adults and children with sickle cell disease experiencing neuropathic pain

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Pregabalin vs placebo

Self‐reported pain relief ‐ S‐LANSS: Possible total scores range from 0 to 24, and a score of 12 or higher is indicative of neuropathic pain. · adults and children with sickle cell disease experiencing neuropathic pain

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Arthroscopic surgery vs sclerosing injection

Participant global assessment of success Not measured · adult participants with patellar tendinopathy

1 finding from 1 review

Surgery for patellar tendinopathy (jumper’s knee) 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Low

Interventions for involving patients in decision‐making about their health care vs attention control

Self‐efficacy · older patients with multi‐morbidity

1 finding from 1 review

Interventions for involving older patients with multi‐morbidity in decision‐making during primary care consultations 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 254 participants
Very low

Animal‐assisted therapy (AAT (live animal)) vs no AAT

Depressive symptoms · people with dementia

1 finding from 1 review

Animal‐assisted therapy for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 83 participants
Low

Animal‐assisted therapy (AAT (live animal)) vs robotic animals

Neuropsychiatric symptoms · people with dementia

1 finding from 1 review

Animal‐assisted therapy for dementia 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 78 participants
Low